Pacific Sun Financial Corp Takes Position in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Share on StockTwits

Pacific Sun Financial Corp purchased a new stake in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,685 shares of the company’s stock, valued at approximately $346,000. Pacific Sun Financial Corp owned approximately 0.16% of SPDR S&P Pharmaceuticals ETF at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of SPDR S&P Pharmaceuticals ETF by 249.5% in the second quarter. JPMorgan Chase & Co. now owns 350,220 shares of the company’s stock valued at $13,784,000 after acquiring an additional 250,000 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of SPDR S&P Pharmaceuticals ETF by 0.5% in the second quarter. Wells Fargo & Company MN now owns 78,026 shares of the company’s stock valued at $3,108,000 after acquiring an additional 394 shares in the last quarter. Cypress Capital Management LLC bought a new position in shares of SPDR S&P Pharmaceuticals ETF in the second quarter valued at approximately $2,407,000. LPL Financial LLC boosted its holdings in shares of SPDR S&P Pharmaceuticals ETF by 2.9% in the second quarter. LPL Financial LLC now owns 48,170 shares of the company’s stock valued at $1,919,000 after acquiring an additional 1,360 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of SPDR S&P Pharmaceuticals ETF by 446.2% in the first quarter. Advisor Group Inc. now owns 22,017 shares of the company’s stock valued at $916,000 after acquiring an additional 17,986 shares in the last quarter.

Shares of SPDR S&P Pharmaceuticals ETF stock traded down $0.16 on Wednesday, hitting $37.39. The company had a trading volume of 1,092 shares, compared to its average volume of 61,949. The business has a 50-day simple moving average of $36.42 and a 200-day simple moving average of $38.89. SPDR S&P Pharmaceuticals ETF has a 52 week low of $34.51 and a 52 week high of $48.98.

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: What can cause a stock to outperform?

Institutional Ownership by Quarter for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brand Asset Management Group Inc. Acquires 359 Shares of Vanguard Global ex-U.S. Real Estate ETF
Brand Asset Management Group Inc. Acquires 359 Shares of Vanguard Global ex-U.S. Real Estate ETF
Brand Asset Management Group Inc. Purchases 1,144 Shares of AT&T Inc.
Brand Asset Management Group Inc. Purchases 1,144 Shares of AT&T Inc.
Brand Asset Management Group Inc. Sells 68 Shares of Boeing Co
Brand Asset Management Group Inc. Sells 68 Shares of Boeing Co
Brand Asset Management Group Inc. Sells 1,170 Shares of Vanguard Russell 1000 Growth ETF
Brand Asset Management Group Inc. Sells 1,170 Shares of Vanguard Russell 1000 Growth ETF
Bailard Inc. Sells 14,158 Shares of Sprott Physical Gold Trust
Bailard Inc. Sells 14,158 Shares of Sprott Physical Gold Trust
Bailard Inc. Reduces Stock Position in BlackRock, Inc.
Bailard Inc. Reduces Stock Position in BlackRock, Inc.


© 2006-2019 Ticker Report